Key result
This review discusses the role of platelets in cardiovascular disease and presents the pharmacological evidence base for using aspirin and clopidogrel to reduce the risk of thrombus formation.
This review summarizes the pharmacology and evidence base for using aspirin and clopidogrel to prevent thrombus formation in patients with coronary heart disease.
May support clinician education on antiplatelet use in CHD; leaves open need for updated comparative trials.
It is established practice to administer antiplatelet drugs to patients with known coronary heart disease (Department of Health, 2000). This pharmacological prevention is based on the findings of a number of randomized controlled trials that have set out to establish a drug of choice and the dose required to reduce the risk of thrombosis formation. The following paper will review the role of platelets in maintaining haemostasis and in cardiovascular diseaseand will discuss how antiplatelet drugs can inhibit the function of platelets and so reduce the risk of thrombosis formation. The pharmacology of aspirin and clopidogrel will be reviewed and the evidence base for their use presented.
No takes yet. Share an insight, caveat, or question.
Helen Walthall (2007) conducted a review in Coronary heart disease. Antiplatelet drugs (aspirin and clopidogrel) was evaluated. This review discusses the role of platelets in cardiovascular disease and presents the pharmacological evidence base for using aspirin and clopidogrel to reduce the risk of thrombus formation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: